Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 15, 2006 - Issue 3
Submit an article Journal homepage
58
Views
1
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension

KATAOKA M, NAGAYA N, SATOH T et al.: A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172(12):1575-1580.

Sabina A Antoniu Clinic of Pulmonary Disease, 30 Dr I Cihac Street, 700115 Iasi, Romania. [email protected]
Pages 327-330 | Published online: 27 Feb 2006

Bibliography

  • HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.
  • BARST RJ, McGOON M, TORBICKI A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):40S-47S.
  • D’ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. (1991) 115(5):343-349.
  • GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157.
  • RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.
  • CLAPP LH, FINNEY P, TURCATO S et al.: Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol. (2002) 26(2):194-201.
  • BADESCH DB, ABMAN SH, AHEARN GS et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(Suppl. 1):35S-62S.
  • BARST RJ, MCGOON M, McLAUGHLIN V et al.: Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41(12):2119-2125.
  • OPITZ CF, WENSEL R, WINKLER J et al.: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. (2005) 26(18):1895-1902.
  • SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165(6):800-804.
  • MURAKAMI S, NAGAYA N, ITOH T et al.: Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. (2006) 290(1):L59-L65.
  • KATAOKA M, NAGAYA N, SATOH T et al.: A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172(12):1575-1580.
  • BUDHIRAJA R, TUDER RM, HASSOUN PM: Endothelial dysfunction in pulmonary hypertension. Circulation (2004) 109(2):159-165.
  • TUDER RM, COOL CD, GERACI MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159(6):1925-1932.
  • LANGLEBEN D, CHRISTMAN BW, BARST RJ et al.: Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am. Heart J. (2002) 143(5):E4.
  • SCHERMULY RT, YILMAZ H, GHOFRANI HA et al.: Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172(3):358-363.
  • SCHERMULY RT, KREISSELMEIER KP, GHOFRANI HA et al.: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. (2004) 169(1):39-45.
  • LALIBERTE K, ARNESON C, JEFFS R, HUNT T, WADE M: Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J. Cardiovasc. Pharmacol. (2004) 44(2):209-214.

Website

  • http://www.fda.gov/cder/foi/nda/2000/20-444S003_Flolan_Prntlbl.pdf Product information on epoprostenol sodium.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.